Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | SFPQ |
| Gene Name: | SFPQ |
| Protein Full Name: | Splicing factor, proline- and glutamine-rich |
| Alias: | DNA-binding P52/P100 complex, 100 kDa subunit; Polypyrimidine tract binding protein associated; Polypyrimidine tract- binding protein-associated splicing factor; Polypyrimidine tract-binding protein-associated-splicing factor; PTB-associated splicing factor; Splicing factor proline/glutamine rich(polypyrimidine tract binding protein associated); Splicing factor proline/glutamine-rich; Splicing factor, proline-and glutamine-rich |
| Mass (Da): | 76149 |
| Number AA: | 707 |
| UniProt ID: | P23246 |
| Locus ID: | 6421 |
| COSMIC ID: | SFPQ |
| Gene location on chromosome: | 1p34.3 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19811 |
| Percent of cancer specimens with mutations: | 0.35 |
| Deregulated in translocations: | Renal cell carcinoma, fusion partner is TFE3. |
| Normal role description: | SFPQ is an RNA-binding protein which is a component of the spliceosome complex required for processing of pre-mRNA to mature form mRNA. SFP1 interacts with NONO and will bind to preMRNA through intronic polypyrimidine tracts. The SFPQ gene locus can participate in a translocation event to form a fusion protein with TFE3, a DNA binding protein, which has been implicated in the development of renal cell carcinoma. |